The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
|Articles|July 25, 2013
Glycemic Targeting
Author(s)Peter Huckfeldt, PhD
In this video segment Dr. Huckfeldt discussed factors contributing to low levels of glycemic control. Patient, medication and physician factors can all effect medication adherence.
Advertisement
Glycemic control reduces the risks of complications in diabetes, but many patients with type 1 diabetes (T1D) still do not achieve their goals of glycemic control, said Dr. Peter Huckfeldt, PhD, Prodessor, Pardee RAND Graduate School. In this video segment Dr. Huckfeldt discussed factors contributing to low levels of glycemic control. Patient, medication and physician factors can all effect medication adherence.
Advertisement
Related to this article
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
3
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
4
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
5